NASDAQ : XERS
Xeris Biopharma Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.96B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.95B |
| Enterprise Value | 2.12B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 182.32M |
| Shares Outstanding | 182.32M |
| Shares Change (YoY) | +10.29% |
| Shares Change (QoQ) | -2.71% |
| Owned by Insiders (%) | 3.43% |
| Owned by Institutions (%) | 61.80% |
| Float | 176.07M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 70.60 |
| PS Ratio | 5.82 |
| Forward PS | 4.51 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 35.08 |
| P/OCF Ratio | 34.49 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.32 |
| EV / EBITDA | 43.48 |
| EV / EBIT | 57.94 |
| EV / FCF | 38.09 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.45 |
| Quick Ratio | 0.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | 5.10 |
| Debt / FCF | 5.20 |
| Interest Coverage | 1.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 6.13% |
| Return on Invested Capital (ROIC) | 8.84% |
| Return on Capital Employed (ROCE) | 16.46% |
| Weighted Average Cost of Capital (WACC) | 8.71% |
| Revenue Per Employee | $771,067 |
| Profits Per Employee | -$39,460 |
| Employee Count | 435 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 0.61 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +11.33% |
| 50-Day Moving Average | 9.31 |
| 200-Day Moving Average | 7.50 |
| Relative Strength Index (RSI) | 60.00 |
| Average Volume (20 Days) | 2,264,513 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.03M |
| Short Previous Month | 7.20M |
| Short % of Shares Out | 4.40% |
| Short % of Float | 4.56% |
| Short Ratio (days to cover) | 2.46 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 335.41M |
| Gross Profit | 290.39M |
| Operating Income | 36.59M |
| Pretax Income | -17.17M |
| Net Income | -17.17M |
| EBITDA | 48.77M |
| EBIT | 36.59M |
| Loss Per Share | -$0.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 121.75M |
| Total Debt | 289.44M |
| Net Cash | -167.70M |
| Net Cash Per Share | -$0.92 |
| Equity (Book Value) | -9.73M |
| Book Value Per Share | -0.06 |
| Working Capital | 85.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 56.61M |
| Capital Expenditures | -938,000 |
| Depreciation & Amortization | 12.18M |
| Net Borrowing | n/a |
| Free Cash Flow | 55.67M |
| FCF Per Share | $0.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.58% |
| Operating Margin | 10.91% |
| Pretax Margin | -5.12% |
| Profit Margin | -5.12% |
| EBITDA Margin | 14.54% |
| EBIT Margin | 10.91% |
| FCF Margin | 16.60% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.29% |
| Shareholder Yield | -10.29% |
| Earnings Yield | -0.95% |
| FCF Yield | 2.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.86 |
| Price Target Difference | 20.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 23.64% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.6 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |